Selinexor
- Generic Name
- Selinexor
- Brand Names
- Xpovio 100 Mg Once Weekly Carton, Nexpovio
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11F6N7O
- CAS Number
- 1393477-72-9
- Unique Ingredient Identifier
- 31TZ62FO8F
- Background
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
- Indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT02530476
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 12
- Registration Number
- NCT02485535
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 320
- Registration Number
- NCT02436707
- Locations
- 🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada
🇨🇦Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Registration Number
- NCT02431351
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- Conditions
- Advanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Fallopian Tube CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell CarcinomaOvarian CarcinomaPathologic Stage III Cutaneous Melanoma AJCC V8
- Interventions
- Drug: CarboplatinDrug: EribulinDrug: FluorouracilDrug: PaclitaxelDrug: CyclophosphamideDrug: CapecitabineBiological: PembrolizumabDrug: OlaparibBiological: NivolumabBiological: IpilimumabDrug: SelinexorDrug: DoxorubicinDrug: TopotecanDrug: PemetrexedDrug: Irinotecan HydrochlorideDrug: OxaliplatinDrug: Leucovorin Calcium
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 221
- Registration Number
- NCT02419495
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT02416908
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
- Conditions
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2022-10-03
- Target Recruit Count
- 21
- Registration Number
- NCT02403310
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2020-09-11
- Target Recruit Count
- 10
- Registration Number
- NCT02402764
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Registration Number
- NCT02389543
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- GSO Global Clinical Research BV
- Target Recruit Count
- 10
- Registration Number
- NCT02384850
- Locations
- 🇧🇪
University Hospital Antwerpen, Antwerpen, Belgium
🇩🇪University Hospital Hamburg, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.